- Home
- UNP vs VRTX Comparison
UNP vs VRTX Comparison
Compare UNP & VRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UNP
- VRTX
- Stock Information
- Founded
- UNP 1862
- VRTX 1989
- Country
- UNP United States
- VRTX United States
- Employees
- UNP N/A
- VRTX N/A
- Industry
- UNP Railroads
- VRTX EDP Services
- Sector
- UNP Industrials
- VRTX Technology
- Exchange
- UNP Nasdaq
- VRTX Nasdaq
- Market Cap
- UNP 130.8B
- VRTX 115.6B
- IPO Year
- UNP N/A
- VRTX 1991
- Fundamental
- Price
- UNP $237.08
- VRTX $457.03
- Analyst Decision
- UNP Buy
- VRTX Buy
- Analyst Count
- UNP 22
- VRTX 26
- Target Price
- UNP $254.27
- VRTX $510.48
- AVG Volume (30 Days)
- UNP 3.0M
- VRTX 1.3M
- Earning Date
- UNP 07-24-2025
- VRTX 07-31-2025
- Dividend Yield
- UNP 2.26%
- VRTX N/A
- EPS Growth
- UNP 6.03
- VRTX N/A
- EPS
- UNP 11.10
- VRTX N/A
- Revenue
- UNP $24,246,000,000.00
- VRTX $11,099,700,000.00
- Revenue This Year
- UNP $2.02
- VRTX $10.48
- Revenue Next Year
- UNP $4.44
- VRTX $10.69
- P/E Ratio
- UNP $21.35
- VRTX N/A
- Revenue Growth
- UNP 0.63
- VRTX 8.98
- 52 Week Low
- UNP $204.66
- VRTX $377.85
- 52 Week High
- UNP $258.07
- VRTX $519.88
- Technical
- Relative Strength Index (RSI)
- UNP 68.82
- VRTX 55.96
- Support Level
- UNP $229.43
- VRTX $439.23
- Resistance Level
- UNP $228.03
- VRTX $446.62
- Average True Range (ATR)
- UNP 3.04
- VRTX 9.11
- MACD
- UNP 1.29
- VRTX 1.27
- Stochastic Oscillator
- UNP 98.17
- VRTX 86.82
About UNP Union Pacific Corporation
Omaha, Nebraska-based Union Pacific is the largest public railroad in North America. Operating on more than 30,000 miles of track in the western two thirds of the US, Union Pacific generated $24 billion of revenue in 2024 by hauling coal, industrial products, intermodal containers, agriculture goods, chemicals, fertilizers, and automotive goods. Union Pacific owns about one fourth of Mexican railroad Ferromex and historically derives roughly 10% of its revenue hauling freight to and from Mexico.
About VRTX Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease. Additionally, Vertex is evaluating small-molecule inhibitors targeting acute and chronic pain using nonopioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.